Jyothy Labs Ltd
The live share price of Jyothy Labs Ltd (JYOTHYLAB) as on 28 Mar 10:24am is ₹439.95 from NSE/BSE.
JYOTHYLAB NSE
₹439.95 ▼-1.42% (-6.35)
As on Mar 28, 2024 03:54 PM IST
Key Metrics
PE Ratio
46.11
PB Ratio
10.42
Dividend Yield
0.68%
Sector PB
9.86
Sector PE
48.68
Sector Div Yld
1.47%
Dividend Yield
Dividend per share for the most recent financial year divided by the close price
About
Jyothy Laboratories Limited is a multi-brand, multi-product FMCG company. It is principally engaged in manufacturing and marketing of fabric whiteners, soaps, detergents, mosquito repellents, scrubber, bodycare and incense sticks.
The following charts display the financial performance of the Jyothy Labs Ltd (JYOTHYLAB) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.
Furthermore, under the Peers section, you can find stocks that are similar to Jyothy Labs Ltd (JYOTHYLAB), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.
✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.
A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.
All smallcases are created and managed by SEBI-registered investment experts.
To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.
Financials
Income Statement
(INR) | Y/Y Change | |
Revenue | 2,532 Cr | +14.33% |
Operating Expense | 71 Cr | +27.8% |
Net Income | 239 Cr | +48.02% |
Net Profit Margin | 9.47% | +29.55% |
Earning Per Share | 6 | +48.04% |
EBITDA | 362 Cr | +35.8% |
Balance sheet
(INR) | Y/Y Change | |
Cash & short-term Inv | 283 Cr | +34.22% |
Total Assets | 2,061 Cr | +1.92% |
Total Liabilities | 510 Cr | -17.62% |
Total Equity | 1,551 Cr | +10.56% |
Shares Outstanding | 36.72 Cr | - |
Price to Book | 4.51 | +15.41% |
Return on Assets | 11.74% | +44.23% |
Return on Capital | 20.14 Cr | +35.35% |
Cash Flows
(INR) | Y/Y Change | |
Net Income | 239 Cr | +48.02% |
Cash from Operations | 328 Cr | +62.22% |
Cash from Investing | -48 Cr | +52.29% |
Cash from Financing | -250 Cr | +50.39% |
Net Change in Cash | 29 Cr | +612.26% |
Free Cash Flow | 293 Cr | +66.06% |
Peers
HINDUNILVR
Hindustan Unilever Ltd
PE Ratio
51.56
1Y Return
▼-8.8%
CELLO
Cello World Ltd
PE Ratio
54.01
1Y Return
▼-2.24%
PQIF
Polo Queen Industrial and Fintech Ltd
PE Ratio
810.77
1Y Return
▲4.64%
MKPL
M K Proteins Ltd
PE Ratio
62.14
1Y Return
▼-61.12%
Latest News
Buy Jyothy Labss; target of Rs 590: Sharekhan
1 month ago on Moneycontrol
Change since news ▼-INF%
Sharekhan is bullish on Jyothy Labs has recommended buy rating on the stock with a target price of Rs 590 in its research report dated February 23, 2024.
Neutral Jyothy Laboratories; target of Rs 500: Motilal Oswal
2 months ago on Moneycontrol
Change since news ▼-INF%
Motilal Oswal recommended Neutral rating on Jyothy Laboratories with a target price of Rs 500 in its research report dated February 01, 2024.
Buy Jyothy Labs; target of Rs 590: Sharekhan
2 months ago on Moneycontrol
Change since news ▼-INF%
Sharekhan is bullish on Jyothy Labs has recommended buy rating on the stock with a target price of Rs 590 in its research report dated January 31, 2024.
2 months ago on Bloomberg Quint
Change since news ▼-INF%
Jyothy Laboratories registered net sales growth of 10.6% YoY to Rs 6,775 million (estimated Rs 6,788 million).
Jyothy Labs Net Profit Jumps 35% To Rs 91 Crore
2 months ago on Bloomberg Quint
Change since news ▼-INF%
FMCG company Jyothy Labs Ltd reported a 35% rise in consolidated net profit to Rs 90.92 crore in the quarter ended December 2023, with revenue increasing by 10.58% to Rs 677.50 crore.
Jyothy Labs Q3 net profit rises 34.9% to Rs 90.9 crore
2 months ago on Moneycontrol
Change since news ▼-INF%
Jyothy Labs Q3 earning: The company’s reported a revenue of Rs 677.5 crore, up 10.6 percent from the year-ago period
FAQs on Jyothy Labs Ltd
How to buy Jyothy Labs Ltd stocks?
You can easily buy the stocks/shares of Jyothy Labs Ltd (JYOTHYLAB) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.
What is the Share Price of Jyothy Labs Ltd?
The stock price of Jyothy Labs Ltd as on 28 Mar 2024 is ₹439.95
What is the 52-week High and Low of Jyothy Labs Ltd?
The 52-week high and low of Jyothy Labs Ltd (JYOTHYLAB) is ₹554 and ₹180.45.
What is the PE and PB ratio of Jyothy Labs Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Jyothy Labs Ltd are 46.11 and 10.42 respectively.
What are the peers or stocks similar to Jyothy Labs Ltd?
The peers or stocks similar to Jyothy Labs Ltd are Hindustan Unilever Ltd, Cello World Ltd, Polo Queen Industrial and Fintech Ltd, M K Proteins Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.
Which sector does Jyothy Labs Ltd belong to?
Jyothy Labs Ltd (JYOTHYLAB) belongs to the FMCG - Household Products sector.
What is the Market Cap of Jyothy Labs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jyothy Labs Ltd (JYOTHYLAB) is ₹16,155 Cr as of 28 Mar 2024
Can't decide whether or not to buy Jyothy Labs Ltd stocks? ⭐️
Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.